Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 16 (2), 141-151, 2015-02
Elsevier BV